FDA Brief

Warning letters Drugs

FDA warning letter to

Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

High riskIssued Jun 3Posted Jun 9Center for Drug Evaluation and Research (CDER)

FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

What happened

FDA inspected the company's API plant in Ezhou City, Hubei Province, China, from November 3 to 7, 2025. Investigators saw numerous scratches and discolored stains on the interior surfaces of vessels that touch the API, and gaps around windows and doors. FDA also found the quality unit was not overseeing manufacturing properly, and called the company's November 28, 2025 response inadequate.

What FDA found

  1. Vessels that touch the API had scratches and discolored stains inside, showing the contact surfaces were breaking down and could shed particles or react with the product.

  2. The company did not show that the materials its equipment is made of can withstand the chemicals used in its process.

  3. The quality unit, the group responsible for overseeing manufacturing quality, did not make sure facilities were maintained or that equipment materials were suitable for use.

  4. There were gaps around windows and doors, so the building was not properly maintained.

  5. The company's response gave no scientific basis for how often it would do preventive maintenance, and did not assess the reactivity of all product-contact surfaces.

  6. Because its methods, facilities and controls do not meet CGMP, the company's APIs are adulterated under the FD&C Act.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA asks the company to reply in writing within 15 working days with a corrective action plan, a retrospective review of all batches within expiry that could be affected, a review of process reactivity with all product-contact surfaces, and a plan to give the quality unit authority and resources. If corrective actions cannot be finished in that time, the company must explain the delay and give a schedule.

Who should pay attention

  • drug makers that buy APIs from this site
  • companies that list this firm as a manufacturer in their applications
  • quality and supply chain teams tracking API suppliers in China

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Hikal Limited

    FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.

    High risk
  2. Jagsonpal Pharmaceuticals Limited

    Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.

    High risk
  3. Tyche Industries Ltd

    FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.

    High risk
  4. Wuhu Nuowei Chemistry Co., Ltd.

    FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.

    High risk